Standard BioTools Announces Collaboration Agreement With Visikol to Offer Multiplex Imaging Mass Cytometry Services
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced a collaboration agreement with Visikol® for service offerings using Imaging Mass Cytometry™.
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 /PRNewswire-PRWeb/ -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced a collaboration agreement with Visikol® for service offerings using Imaging Mass Cytometry™.
The agreement is an expansion of the relationship established in 2020 under which Visikol will offer IMC services to clients from its site in Hampton, NJ. Visikol, a contract research services company focused on advanced tissue imaging and advanced cell culture assays, services all 20 of the top pharmaceutical companies. Visikol will leverage the Standard BioTools™ Hyperion+™ Imaging System, based on Imaging Mass Cytometry (IMC™), in its multiplex tissue imaging services. This initiative is supported by Visikol's digital pathology services, which aim to transform large imaging-based datasets into actionable insights.
Recently, the demand for tools to evaluate the complex immune cell landscape has grown dramatically as researchers, biotech companies, and pharmaceutical companies look to develop immuno-oncology therapeutics and better understand the intricate interplay between the immune system and disease.
Multiplex tissue imaging is a key tool that researchers can use to characterize a wide range of immune cell and tissue-specific biomarkers simultaneously. Standard BioTools has developed a version of this technology, IMC that currently allows for 40-plus markers to be detected on a single slide with an unprecedented level of sensitivity, quantification, and absence of autofluorescence. In addition, IMC's rapid panel design capability is particularly well suited to applications within contract research organizations.
"As a company that is focused on advanced tissue imaging, we are excited to add IMC to our portfolio of tools and to work closely with Standard BioTools, as it will allow us to better meet the needs of our clients," said Visikol CEO Michael Johnson, PhD. "IMC provides our clients with the unique ability to image many markers simultaneously while providing an unparalleled level of image quality."
"IMC is one of the essential technologies that Standard BioTools provides," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "The valuable relationship with Visikol broadens the use of IMC for spatial omics studies, offering a vital tool in the acceleration of drug discovery and development in particular when dealing with precious and scarce patient biopsies. We look forward to working with the Visikol team to help their pharma clients uncover important spatial relationships within the tissue microenvironment."
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the potential benefits of research conducted using Standard BioTools products and technologies and anticipated benefits to Standard BioTools of an expanded collaboration. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; potential product performance and quality issues; intellectual property risks; competition; uncertainties in contractual relationships; and reductions in research and development spending or changes in budget priorities by customers. Information on these and additional risks and uncertainties and other information affecting Standard BioTools' business and operating results is contained in its Annual Report on Form 10-K for the year ended December 31, 2021, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Standard BioTools disclaims any obligation to update these forward-looking statements except as may be required by law.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm, is driven by a bold purpose –Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at http://www.standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, "Unleashing tools to accelerate breakthroughs in human health," CyTOF, Hyperion, Hyperion+, Imaging Mass Cytometry and IMC are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
About Visikol
Visikol is a contract research services company that is focused on accelerating the drug discovery and development process through providing its clients with advanced tissue imaging and advanced cell culture services. Today, Visikol counts the top 20 pharmaceutical companies as clients and has been instrumental in dozens of drug discovery programs. The company provides end-to-end services that include 3D tissue imaging, multiplex tissue imaging, digital pathology, high-content imaging, 2D cell culture assays, 3D cell culture assays, and ex vivo tissue slice assays. Visikol's expertise lies in both transforming tissues into actionable insights and bridging the gap between in vitro assays and in vivo results through the use of best in-class cell culture models. In addition to its services, Visikol sells a suite of tissue clearing reagents and kits as well as the HUREL® Micro Liver portfolio of primary hepatocyte liver models. Learn more at http://www.visikol.com.
Available Information
Standard BioTools uses its website (standardbio.com), investor site (investors.standardbio.com), corporate Twitter account (@Standard_BioT), Facebook page (facebook.com/StandardBioT), and LinkedIn page (linkedin.com/company/standard-biotools) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools' website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts.
Investors:
Peter DeNardo
415 389 6400
[email protected]
Source: Standard BioTools Inc.
Media Contact
Michael Johnson, Visikol, 1 8006158474, [email protected]
SOURCE Visikol
Share this article